In vivo studies showed that intravenous DNAzymes suppressed pulmonary vasculature remodeling, such as the development of occlusive neointimal lesions, and decreased PAH progression by downregulating EGR1 and lowering PDGF-BB and TGF-b1 level. Here, TGFB1 is linked to pulmonary arterial hypertension.